(Q40886133)

24 September 2017

1 reference

title

Experimental chemotherapeutic agents for the treatment of colorectal carcinoma (English)

1 reference

24 September 2017

1 reference

S O'Reilly

1

1 reference

24 September 2017

E K Rowinsky

series ordinal

2

1 reference

24 September 2017

publication date

1 August 1997

1 reference

Hematology / Oncology Clinics of North America

24 September 2017

published in

1 reference

24 September 2017

volume

11

1 reference

24 September 2017

issue

4

1 reference

24 September 2017

page(s)

721-758

1 reference

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Pharmacokinetics of ftorafur after intravenous and oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Matrix metalloproteinase inhibition: a review of anti-tumour activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Phase ii evaluation of ftorafur in previously untreated colorectal cancer: A southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

'Tomudex' (ZD1694): A novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Population study of dihydropyrimidine dehydrogenase in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

A genetic model for colorectal tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Folate-based thymidylate synthase inhibitors as anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

A potent antitumour quinazoline inhibitor of thymidylate synthetase: Synthesis, biological properties and therapeutic results in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Phase II trial of UFT in advanced colorectal and gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Metalloproteinases and their inhibitors in matrix remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Chemotherapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Current status of adjuvant chemotherapy for colorectal cancer. Can molecular markers play a role in predicting prognosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Report on nationwide pooled data and cohort investigation in UFT phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Cancer statistics, 1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some 3-amino- and 3-methylbenzo[f]quinazolin-1(2H)-ones

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Fluorouracil: biochemistry and pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

The current status of camptothecin analogues as antitumor agents

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Preclinical and clinical aspects of biomodulation of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

The effects of camptothecin on mammalian DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

CPT-11 Converting Enzyme from Rat Serum: Purification and Some Properties

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970458-5

7 January 2021

10.1016/S0889-8588(05)70458-5

Identifiers

DOI

1 reference

24 September 2017

1 reference